EUVIMEDEUVIMED entdecken
Klinische Studie

Benefits of Prokinetics, Gastroparesis Diet, or Neuromodulators Alone or in Combination for Symptoms of Gastroparesis

William L Hasler, Allen A Lee, Baharak Moshiree, Brian C Surjanhata, Satish Rao, Henry P Parkman, Linda A Nguyen, Irene Sarosiek, John M Wo, Michael I Schulman, Richard W McCallum, Braden Kuo

Clinical Gastroenterology and Hepatology · 2024-04 · 22 (4) · 867-877.e12

DOI: 10.1016/j.cgh.2023.10.014 ↗

Kurz gefasst

Klinische Studie in der Zeitschrift Clinical Gastroenterology and Hepatology, 2024-04. Verfasst von William L Hasler und 11 weiteren Autor:innen. Beteiligte Einrichtung: Gastroenterology and Hepatology, Mayo Clinic Arizona, Scottsdale, Arizona. Electronic address: Hasler.William@mayo.edu. Hauptthemen laut MEDLINE: Gastroparesis. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 26 Literaturangaben. Gefördert von: Medtronic Inc, Medtronic.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND & AIMS: Prokinetics have limited effectiveness for treating symptoms of gastroparesis. Thus, alternative or adjunct therapies, such as gastroparesis diets or neuromodulators, are often prescribed. Their therapeutic benefits alone or in combination remain unclear. METHODS: One hundred and twenty-nine patients with symptoms of gastroparesis underwent wireless motility capsule gastric emptying time and gastric emptying scintigraphy. Based on test results, changes in therapy were recommended. Changes in Gastroparesis Cardinal Symptom Index (GCSI) and individual symptom scores over 6 months were related to recommendations for prokinetics, gastroparesis diet, or neuromodulators given as solo new therapies or in dual combinations. Multivariate analyses were performed to adjust for gastric emptying and other variables. RESULTS: In the whole group regardless of therapy, GCSI scores decreased by 0.53 points (interquartile range, -1.25 to 0.05; P < .0001) over 6 months. GCSI did not decrease for prokinetics as solo new therapy (P = .95). Conversely, neuromodulators as solo therapy decreased GCSI scores (P = .04) and all individual symptoms except nausea/vomiting (P = .86). Prokinetics combined with gastroparesis diets or neuromodulators improved GCSI scores (P ≤ .04) and most individual symptoms. Adjusting for gastric emptying time on multivariate analyses showed greater GCSI decreases for nondelayed emptying for neuromodulators as solo new therapy (P = .01). Gastric emptying scintigraphy, gender, diabetes, and functional dyspepsia did not influence responses to any treatment. CONCLUSIONS: Initiating prokinetics as solo new therapy had little benefit for patients with symptoms of gastroparesis. Neuromodulators as the only new therapy decreased symptoms other than nausea and vomiting, especially with nondelayed gastric emptying. Adding gastroparesis diets or neuromodulators to prokinetics offered relief, suggesting that combination therapies may be more useful in managing these patients. (ClinicalTrials.gov NCT02022826.).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GastroparesisHumansDietGastric EmptyingNauseaNeurotransmitter AgentsTreatment OutcomeVomiting

Stichwörter der Autor:innen

Gastric Emptying ScintigraphyMultivariate AnalysesSymptom OutcomesWireless Motility Capsule

Substanzen

Neurotransmitter Agents

Autor:innen und Institutionen

  • Gastroenterology and Hepatology, Mayo Clinic Arizona, Scottsdale, Arizona. Electronic address: Hasler.William@mayo.edu.
  • Division of Gastroenterology, University of Michigan Health System, Ann Arbor, Michigan.
  • Atrium Health Wake Forest Baptist, Morehead Medical Plaza, Charlotte, North Carolina.
  • Division of Gastroenterology, Massachusetts General Hospital, Boston, Massachusetts.
  • Division of Gastroenterology and Hepatology, Medical College of Georgia, Augusta, Georgia.
  • Section of Gastroenterology, Temple University, Philadelphia, Pennsylvania.

Förderung

  • Medtronic Inc
  • Medtronic

Zitieren

APA

Hasler, W. L., Lee, A. A., Moshiree, B., Surjanhata, B. C., Rao, S., Parkman, H. P., Nguyen, L. A., Sarosiek, I., Wo, J. M., Schulman, M. I., McCallum, R. W., & Kuo, B. (2024). Benefits of Prokinetics, Gastroparesis Diet, or Neuromodulators Alone or in Combination for Symptoms of Gastroparesis. Clinical Gastroenterology and Hepatology, 22(4), 867-877.e12. https://doi.org/10.1016/j.cgh.2023.10.014

Vancouver

Hasler WL, Lee AA, Moshiree B, Surjanhata BC, Rao S, Parkman HP, et al. Benefits of Prokinetics, Gastroparesis Diet, or Neuromodulators Alone or in Combination for Symptoms of Gastroparesis. Clinical Gastroenterology and Hepatology. 2024;22(4):867-877.e12. doi:10.1016/j.cgh.2023.10.014

BibTeX
@article{Hasler2024,
  author = {Hasler, William L and Lee, Allen A and Moshiree, Baharak and Surjanhata, Brian C and Rao, Satish and Parkman, Henry P and Nguyen, Linda A and Sarosiek, Irene and Wo, John M and Schulman, Michael I and McCallum, Richard W and Kuo, Braden},
  title = {Benefits of Prokinetics, Gastroparesis Diet, or Neuromodulators Alone or in Combination for Symptoms of Gastroparesis},
  journal = {Clinical Gastroenterology and Hepatology},
  year = {2024},
  volume = {22},
  number = {4},
  pages = {867--877.e12},
  doi = {10.1016/j.cgh.2023.10.014}
}
Kostenlos starten →